symbol: MTLF
647
Cycle B.N.:
105,017
Change:
-7.16 %
At:
17:24
True to:
25/05/2022

Company profile

Matricelf is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions. The company was established in 2019 by Professor Tal Dvir of the Laboratory for Tissue Engineering and Regenerative Medicine from Tel Aviv University. Our patented technology is a product of eight years of research and $12 million in grants.

Download Materials

Investor Presentation - Heb
Investor Presentation - En
Matricelf 2021 financial report
תשקיף

Press Release

Matricelf (TASE:MTLF) announced today that scientists from Sagol Center for Regenerative Biotechnology at Tel Aviv University have engineered 3D spinal cord tissues and implanted them in mice model with long-term chronic paralysis.
February 7, 2022
מטריסלף הצליחה להפוך תאי אדם בוגרים לתאי גזע; המניה מזנקת ב-11%
May 7, 2022
Matricelf is happy to announce that it has completed and signed an exclusive, global, license agreement with Ramot, the technology transfer arm of Tel Aviv University for the development and commercialization of a novel technology in 3D bioprinting of tissues and organs.
January 31, 2022
We are pleased to announce that we completed another successful usability study with our human implants to bridge spinal cord injury in a live porcine.
January 16, 2022
Matricelf’s US Patent and Trademark office officially granted a patent titled “PARTICLES COMPRISING DECELLULARIZED OMENTUM”
January 4, 2022
Matricelf is pleased to announce that it has appointed Prof. Mark Tuszynski to its Scientific Advisory Board
January 2, 2022

Events

H.C. Wainwright & Co., LLC BioConnect Conference.
January 11, 2022
BIO CEO & Investor conference.
February 10, 2020
Global Startup Competition.
January 7, 2020
ICI 2019.
December 9, 2019
Seed Award.
August 27, 2019